Abionyx Pharma (ABNX.FP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [Euronext FR]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [Euronext FR]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2019 | 12-2018 | 12-2017 | 12-2016 | 12-2015 | |
| Cash Flows From Operating Activities | |||||
| Other Working Capital | -1,304 | -316 | -895 | -733 | 1,230 |
| Other Operating Activity | -2,646 | -5,685 | -8,197 | -18,464 | -14,941 |
| Operating Cash Flow | $-3,950 | $-6,001 | $-9,092 | $-19,197 | $-13,711 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | 0 | -10 | 0 | -5 | -161 |
| Purchase Sale Intangibles | 0 | 0 | -213 | 0 | -10 |
| Investing Cash Flow | $0 | $-10 | $-213 | $-5 | $-171 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 250 | 0 | 750 | 0 | 0 |
| Debt Repayment | -400 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 973 | 1,195 | 152 | 925 | 49,478 |
| Common Stock Repurchased | N/A | N/A | N/A | N/A | -485 |
| Financing Cash Flow | $823 | $1,195 | $902 | $925 | $48,993 |
| Exchange Rate Effect | 0 | 1 | 0 | 1 | -2 |
| Beginning Cash Position | 11,457 | 16,272 | 24,675 | 42,951 | 7,843 |
| End Cash Position | 8,331 | 11,457 | 16,272 | 24,675 | 42,951 |
| Net Cash Flow | $-3,127 | $-4,816 | $-8,403 | $-18,277 | $35,111 |
| Free Cash Flow | |||||
| Operating Cash Flow | -3,950 | -6,001 | -9,092 | -19,197 | -13,711 |
| Capital Expenditure | N/A | -23 | -213 | -5 | -171 |
| Free Cash Flow | -3,950 | -6,024 | -9,305 | -19,202 | -13,882 |